Peter I Karachunski

Keyphrases

1. Duchenne muscular Dystrophy 100%
2. Acetylcholine Receptor (AChR) 62%
3. Myasthenia Gravis 46%
4. CD4 Cells 33%
5. Epitope 33%
6. CD4+ 31%
7. Torpedo 30%
8. Phase II Trial 22%
9. T Epitopes 22%
10. T Cells 17%
11. Epitope Sequence 17%
12. Pathogenic Variants 14%
13. Disease Progression 13%
14. Ataluren 13%
15. Prednisone 13%
16. Muscular Dystrophy 13%
17. Placebo 12%
18. Muscle Acetylcholine Receptor 12%
19. Motor Function 12%
20. Nasal Administration 12%
21. Clinical Spectrum 12%
22. Rodents 12%
23. Prednisolone 12%
24. Deflazacort 12%
25. Nonsense mutation Duchenne muscular Dystrophy 12%
26. Forced Vital Capacity 12%
27. Dystrophinopathy 12%
28. Glucocorticoid Therapy 12%
29. 6-minute Walk Distance (6MWD) 11%
30. Acetylcholine Receptor Antibody 11%
31. B-epitopes 11%
32. TANGO2 11%
33. Domagrozumab 11%
34. Open-label Extension 11%
35. Clinical Phenotype 11%
36. Facioscapulohumeral muscular Dystrophy 11%
37. Randomized Phase II Trial 11%
38. Placebo-controlled 11%
39. Non-ambulatory 11%
40. Nicotinic Acetylcholine Receptor (nAChR) 11%
41. Dystrophin 11%
42. Early Onset 11%
43. Immunization 10%
44. C57BL 9%
45. Spinal muscular Atrophy 9%
46. Motor Assessment 9%
47. Interleukin-4 (IL-4) 9%
48. Wild Mice 9%
49. Loss of Ambulation 8%
50. Young children 8%